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of these patients in the community compared to patients
in the severe stage who tend to be institutionalized. Based
on its slowing of Alzheimer’s patient deterioration,
rivastigmine would save annually $268 million (14.2%)
of total productivity costs to employers and $1.41 billion
(14.2%) of total income losses to caregivers. Rivastig-
mine’s effects in slowing Alzheimer’s patient deterioration
are strongest in the moderate disease stage. Coupled with
higher employment-related costs in this stage, rivastig-
mine’s cost-saving effects would also be highest in the
moderate disease stage.
CONCLUSION: Employment-related costs of informal
Alzheimer’s caregiving are substantial. Therapies such as
rivastigmine can signiﬁcantly reduce these costs, particu-
larly in the moderate disease stage where costs and
rivastigmine’s effects are greatest.
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OBJECTIVES: The purpose of this study is to estimate
the impact of anxiety on absenteeism and employment 
in the United States using the 1997 Medical Expenditure
Panel Survey.
METHODS: Anxiety cases were deﬁned by self-report 
by survey respondents who saw a physician during the
previous year for a condition and recorded as a three 
digit ICD-9 code (Anxiety disorders = 300). National
population estimates were derived from patient level
weights as determined by a nationally representative
sample of the non-institutionalized civilian population of
the United States in 1997. Descriptive analyses were used
to examine individual demographic, socioeconomic, and
co-morbidity characteristics of those respondents with
anxiety.
RESULTS: Of the 1997 US representative population of
34,551 survey respondents from the MEPS analysis, 848
persons, representing 684,312 persons (2.5% of the US
population), reported having anxiety. Anxiety respon-
dents were more likely to be female (69.2%), Caucasian
(83.6%), and older than the overall population (mean age
44 years vs. 33 years). Among respondents aged 18–64
years, persons with anxiety were less likely to work than
those without anxiety (males 59.1% vs. 70.8%; females
53.5% vs. 56.9%). Those persons reporting anxiety were
more likely to have missed days from work 39.1% vs.
28.2% for females and 35.9% vs. 27.5% for males.
Persons with anxiety were more likely to change jobs
through the year and a half interview reference period
(57.8% vs.49.2% for females; 63.9% vs. 57.4% for
males).
CONCLUSIONS: Differences are seen at the workplace
in patients with and without anxiety disorders. Patients
with anxiety most often are female and have a greater fre-
quency of not being employed, missing time from work,
and changing jobs.
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OBJECTIVE: An estimated 50% of Americans are
exposed to at least one traumatic event in a lifetime. Of
those, 20% experience post-traumatic stress disorder
(PTSD). Approximately 50% of patients with PTSD have
comorbid major depression disorder. This study exam-
ined the cost differential between patients with major
depressive disorder (MDD) only, PTSD only and patients
with comorbid MDD and PTSD.
METHODS: A retrospective study of patients with MDD
and PTSD was performed using 1996 to 1999 claims
from the MarketScan Database, with private sector health
data from approximately 100 payers. Three cohorts of
patients were created: 1) patients with MDD (ICD-9-CM
296.2, 296.3, 300.4, or 311); 2) patients with PTSD
(ICD-9-CM 309.81); and 3) patients with both MDD and
PTSD. Patients had to also have a prescription drug claim
for an antidepressant within 30 days of diagnosis. During
the 6 month follow-up, healthcare utilization and expen-
ditures for inpatient, outpatient, emergency room, and
outpatient drugs were calculated. Total expenditures were
compared. ANOVA was used to assess the statistical 
signiﬁcance of differences in expenditures.
RESULTS: A total of 24,955 patients with fee-for-service
health coverage were identiﬁed. Of those, 24,156 were
diagnosed with MDD, 196 with PTSD, and 603 had 
co-occurring MDD and PTSD. The mean total expendi-
ture for patients with MDD, PTSD, and MDD with PTSD
were $3,407, $3,714, $5,723 respectively (p < 0.05).
PTSD was signiﬁcantly associated with increased expen-
ditures after stratifying for gender, age, and geographic
region.
CONCLUSION: Costs associated with MDD and PTSD
are substantial. The total health care expenditures of
patients with PTSD were signiﬁcantly higher than 
expenditures for patients with MDD alone. Patients 
with comorbid depression and PTSD had signiﬁcantly
increased expenditures than patients with one condition.
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OBJECTIVES: Treatment-resistant depression (TRD)
occurs in 10%–20% of all diagnosed cases of major
depression. There are currently no speciﬁc codes to 
identify TRD in administrative databases. The objectives
of this study were to: (1) apply an algorithm to identify
TRD-likely patients among a population of Saskatchewan
Health (SH) recipients who had a claim with a depression
diagnosis and at least one antidepressant prescription
between January 1, 1993 and December 31, 1995; (2)
determine the prevalence of TRD in this population; and
(3) assess differences in costs and resource utilization for
TRD-likely versus TRD-unlikely patients.
METHODS: A TRD-likelihood algorithm based on anti-
depressant switches, titrations and augmentation therapy
was applied in a SH claims sample of 13,533 pharmaco-
logically treated depressed patients to determine which
were likely to have TRD. Comparisons between the TRD-
likely and TRD-unlikely groups in resource utilization
and annualized costs were made using Wilcoxon tests for
continuous variables and chi-square tests for categorical
variables.
RESULTS: 863 patients (6.4%) were identiﬁed as TRD-
likely. TRD-likely patients had signiﬁcantly higher costs
and resource utilization compared to the TRD-unlikely
patients for all measured outcomes. Median annualized
costs per patient for hospital, physician and prescription
services were CAD$1403 for TRD-likely and CAD$548
for TRD-unlikely (p < .0001). The median number 
of health claims per patient was 51 for TRD-likely 
compared to 27 for TRD-unlikely (p < .0001). TRD-likely
patients had more physician visits (p < .0001) and hospi-
tal admissions (p < .0001) and had a longer median length
of stay (8 days vs. 4 days, p < .0001).
CONCLUSION: Patients who have TRD consume 
signiﬁcantly more medical resources and have higher
medical costs associated with their treatment than non-
TRD patients. Additional research is needed to under-
stand the biological and behavioral differences between
these populations. Successful management of this sub-
population of depressed patients may reduce treatment
costs and resource consumption for depression.
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OBJECTIVES: This study investigates the impact of
Attention-Deﬁcit/Hyperactivity Disorder (“ADHD”) on
the prevalence and costs of accidents. The unique contri-
bution of this research is that it estimates a model that
predicts the probability of having an accident for indi-
viduals with and without ADHD.
METHODS: Administrative claims data from a large
employer (n > 100,000) were analyzed. ADHD patients
were identiﬁed as beneﬁciaries with one or more claims
for ADHD in the study period (1996–98). The ADHD
patient sample was compared to a matched control
sample. In addition to descriptive analysis, multivariate
analysis involving logistic regression was used to estimate
a model of the probability of having an accident.
RESULTS: ADHD patients have a greater incidence of
accidents than their controls (32% v. 20%). However,
given that a patient has an accident, the average number
of accident claims is the same between both groups (3.6
v. 3.5). Accident speciﬁc costs are greater for ADHD
patients than controls ($209 vs. $131) because patients
with this condition are more likely to have accidents.
Among patients with accident claims, ADHD patients
and controls had statistically similar costs. The multi-
variate analysis conﬁrms the utilization patterns found in
the descriptive analysis. The odds of having an accident
for ADHD patients are 1.7 times as great as that for con-
trols after taking account of all the other variables.
CONCLUSIONS: ADHD is a signiﬁcant predictor of
having an accident. However, given that a person has an
accident, ADHD patients generally have a similar number
of accident claims and costs as their controls.
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OBJECTIVE: To evaluate persistency with various
antipsychotic monotherapies and whether improved per-
sistency translates into cost savings.
METHODS: We use longitudinal claims data from 180
MCOs to identify 220 quetiapine patients who were new
to therapy and initiated on monotherapy between
October 1, 1997 and March 31, 1999 and tracked
through June 2000. Matched patients were randomly
selected to populate three comparator groups: haloperi-
dol, risperidone, and olanzapine. Primary endpoint was
the duration on monotherapy. Secondary endpoint was
whether costs decreased with greater duration on
monotherapy. Psychiatric related costs were also aggre-
gated by type of service. Analyses consisted of Cox 
proportional hazard models for time on monotherapy
and linear regressions for cost. Three subset analyses were
performed: patients aged 45 to 64, psychotic patients 65
or older, and patients with bipolar disorder.
RESULTS: For psychotic patients 45 to 64 years old, que-
tiapine-treated patients remained on treatment for 284
days vs. 261 days for risperidone (P = 0.71), 284 vs. 144
for haloperidol (P < 0.01), and 284 vs. 147 for olanzap-
ine (P < 0.01). Corresponding cost savings for this age
